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REPORT
A Novel Mutation in FGFR3 Causes Camptodactyly, Tall Stature,
and Hearing Loss (CATSHL) Syndrome
Reha M. Toydemir, Anna E. Brassington, Pınar Bayrak-Toydemir, Patrycja A. Krakowiak,
Lynn B. Jorde, Frank G. Whitby, Nicola Longo, David H. Viskochil, John C. Carey,
and Michael J. Bamshad
Activating mutations of FGFR3, a negative regulator of bone growth, are well known to cause a variety of short-limbed
bone dysplasias and craniosynostosis syndromes. We mapped the locus causing a novel disorder characterized by camp-
todactyly, tall stature, scoliosis, and hearing loss (CATSHL syndrome) to chromosome 4p. Because this syndrome reca-
pitulated the phenotype of the Fgfr3 knockout mouse, we screened FGFR3 and subsequently identiﬁed a heterozygous
missense mutation that is predicted to cause a p.R621H substitution in the tyrosine kinase domain and partial loss of
FGFR3 function. These ﬁndings indicate that abnormal FGFR3 signaling can cause human anomalies by promoting as
well as inhibiting endochondral bone growth.
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Fibroblast growth factor receptor 3 (FGFR3) is one of ﬁve
distinct membrane-spanning tyrosine kinases that partic-
ipate in a variety of developmental processes. Mutations
in FGFR3 cause at least half a dozen different disorders,
including achondroplasia (ACH [MIM 100800]), hypo-
chondroplasia (HCH [MIM 146000]), thanatophoric dys-
plasia I and II (MIM 187600), Muenke syndrome (MIM
602849), Crouzon syndrome with acanthosis nigricans
(MIM 187600), severe ACH with developmental delay
and acanthosis nigricans (SADDAN) syndrome,1 and
lacrimo-auriculo-dental-digital (LADD [MIM 149730])
syndrome.2,3 FGFR3 is a negative regulator of bone growth,
and all mutations characterized to date cause constitutive
FGFR3 activation and impair endochondral bone growth.3
We evaluated a large Utah pedigree in which 27 living
affected family members spanning four generations (from
a total of 35 affected individuals in seven generations; see
ﬁg. 1) were affected with dominantly inherited campto-
dactyly, tall stature, and hearing loss or CATSHL (pro-
nounced “cat-shul”) syndrome (ﬁg. 2). Phenotypic infor-
mation and DNA were available from 20 of 27 affected
individuals. Adult height in males was 197th percentile
in 5 of 5 men, with a mean height of 77 inches, and adult
height in females was 175th percentile in 9 of 9 and 197th
percentile in 8 of 9 women, with a mean height of 70
inches. Camptodactyly of the hands and/or feet (ﬁg. 2)
was present in 18 (90%) of 20 individuals, and 17 (85%)
of 20 had hearing loss (14 of 20 were documented as hav-
ing hearing loss, and 3 of 20 acknowledged havinghearing
loss but refused formal testing). Of 20 individuals, 12
(60%) had developmental delay and/or mental retarda-
tion, and several of these had microcephaly (head circum-
ference !2nd percentile). Several had scoliosis and/or a
pectus excavatum (ﬁg. 2), although the frequency of oc-
currence might be underestimated because many family
members elected not to undergo chest and/or spine ex-
amination. No individual had characteristics of LADDsyn-
drome or craniosynostosis syndromes caused by muta-
tions in FGFR3. Marfan syndrome was considered a
possible diagnosis, but no affected individuals who were
examined had severe myopia, lens dislocation, or aortic-
root abnormalities. Therefore, the diagnosis of Marfan
syndrome was excluded.
Radiographic ﬁndings included tall vertebral bodies
with irregular borders and broad femoral metaphyses with
long tubular shafts (data not shown). Several affected in-
dividuals had a single osteochondroma of the femur, the
tibia, or a phalanx; pectus abnormalities; and/or severe
thoracolumbar kyphoscoliosis (ﬁg. 2). On audiological
exam, each tested individual had bilateral sensorineural
hearing loss and absent otoacoustic emissions (ﬁg. 3). By
report, the hearing loss was congenital or developed in
early infancy, progressed variably in early childhood, and
ranged from mild to severe. Computed tomography and
magnetic resonance imaging revealed that the brain, mid-
dle ear, and inner ear were structurally normal.
To identify the locus for CATSHL syndrome, we per-
formed a genomewide linkage scan, on 20 affected indi-
viduals, that revealed a signiﬁcantly positive LOD score
of 3.76 (recombination fraction [v] 0.001) with marker
D4S412 (table 1), located on the tip of chromosome 4p.
A multipoint LOD score estimated from markers saturat-
ing this region was 5.1 and reached its maximum atD4S43
(table 2). No other region of the genome harboredmarkers
with a signiﬁcantly positive LOD score. Haplotype analysis
delimited a critical interval of ∼7Mb (ﬁg. 1) that contained
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Figure 2. Clinical characteristics of CATSHL syndrome. A, Tall stature, pectus excavatum, and scoliotic deformity of the spine. Camp-
todactyly of the hands (B and C) and feet (D and E). F, Anterior-posterior radiograph of the thoracolumbar spine, showing ∼80 lateral
curvature of the lumbar spine. G, Radiograph of the hand of an individual with camptodactyly.
Figure 3. Representative audiograms of two individuals with CATSHL syndrome that demonstrate sensorineural hearing loss. Pure-
tone response in the left ear is indicated by a cross (#) and response in the right ear by an open circle (). Responses in the 500–
8,000 Hz range were obtained in the mild sloping to severe hearing loss range, bilaterally.
∼30 genes, including FGFR3 (Genbank accession number
NM_000142). Because the features of CATSHL syndrome
overlapped with those of mice homozygous for a Fgfr3
null allele,4,5 we screened affected individuals for FGFR3
mutations by direct DNA sequencing.
In all affected family members tested ( ), we dis-np 20
covered a GrA missense mutation at nucleotide position
1862 (c.1862GrA) that creates a novel DraIII restric-
tion site (ﬁg. 4) and a histidinerarginine substitution
(p.R621H). R621 is located in the catalytic loop of the
tyrosine kinase domain of FGFR3, and it is invariant in
the tyrosine kinase superfamily (ﬁg. 4c). No unaffected
family members had this variant, nor was it found in 500
chromosomes from individuals matched for geographic
ancestry (Western Europe).
The catalytic loop plays a critical role in the transfer of
a phosphate ion to its target sites. On the basis of ho-
mology modeling done using the crystal structure of
FGFR1, the homologous amino acid residue (i.e., R627) is
predicted to be critical for the transfer of phosphate.6 The
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Table 1. Two-Point Linkage Data for All
Chromosomes
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 4. Identiﬁcation of loss-of-function mutation in FGFR3 that causes CATSHL syndrome. A, A heterozygous GrA FGFR3 mutation
creates a novel DraIII restriction site. B, Restriction digest with DraIII that conﬁrmed homozygosity for the uncut wild-type FGFR3
allele (419 bp) in unaffected individuals (open symbols), whereas affected individuals (ﬁlled symbols) were heterozygous for a wild-
type allele (419 bp) and a mutant allele that cut into two fragments (318 and 101 bp). C, Amino acid alignment of different FGFRs.
Arginine at codon 621 of the activation domain is conserved among human FGFR1, -2, -3, and -4 (top), in all vertebrate FGFR3s
characterized to date (middle), and in other receptor tyrosine kinases (bottom).
p.R621H substitution may therefore interfere with the
ability of FGFR3 to transfer phosphate to its peptide sub-
strate, resulting in loss of function (ﬁg. 5). This prediction
is supported by experiments in which site-directed mu-
tagenesis of the homologous amino acid residue in the
kinase domain of the insulin receptor (i.e., R1136) and the
C-terminal Src Kinase virtually inactivates the receptor.7,8
The anomalies observed in humans with p.R621H re-
capitulate the defects identiﬁed in Fgfr3/ mice.4,5 The
skeletal phenotype of Fgfr3/ mice is characterized by
elongated long bones (particularly the femur) and long
vertebral bodies that predispose the animals to thoracic
kyphoscoliosis and tail kinks. Like the Fgfr3/ mice, only
bones formed by endochondral ossiﬁcation are affected
in CATSHL syndrome, and the bones most notably af-
fected are the long bones and vertebral bodies. Fgfr3/
mice also exhibit profound sensorineural deafness that is
caused by cochlear defects, including absence of inner and
outer pillar cells in the organ of Corti and reduced in-
nervation of the outer hair cells.4,5 However, the middle
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Table 2. Results of the Multipoint
Linkage Analysis
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 5. A, Ball-and-stick model of the active-site region of the catalytic domain of FGFR1. The model is based on the 0.2-nm crystal
structure of the tyrosine kinase domain of the human FGFR1 (RSCB Protein Data Bank entry 1FGK). R627 of FGFR1 is homologous to
R621 of FGFR3. B, Hypothetical model of FGFR3, showing position of histidine side chain when substituted for R621.
ear ossicles and the gross structure of the inner ear of
Fgfr3/ mice are normal. Likewise, individuals with
p.R621H had sensorineural hearing loss, normal conduc-
tive hearing, and no gross abnormalities of the middle or
inner ear. In contrast to the static deafness observed in
Fgfr3/ mice, the hearing loss in individuals with the
p.R621H substitution was progressive. This differencemay
be a result of the residual activity of the wild-type copy
of FGFR3 in individuals with CATSHL syndrome. It also
suggests that the support cells of the organ of Corti might
require FGFR3 for maintenance as well as formation, an
inference consistent with the expression of Fgfr3 in pillar
cells of the adult rat.9 This requirement may be dose-sen-
sitive, because some individuals with constitutively acti-
vating mutations in FGFR3 also develop sensorineural
hearing loss.10
The skeletal phenotypes of both Fgfr3/ mice and in-
dividuals with CATSHL syndrome also are similar to those
of sheep with a naturally occurring condition called
“ovine hereditary chondrodysplasia” or “spider lamb syn-
drome” (SLS).11,12 SLS is a codominant condition charac-
terized by modestly increased long-bone length in het-
erozygotes and elongated “spider-like” legs, a “humped
and twisted spine,” ﬂexion contractures of the legs, and
deformed ribs and sternebra in homozygotes.12 SLS is
caused by a substitution of glutamic acid for valine at
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amino acid position 700 (p.V700E) in the tyrosine kinase
of Fgfr3, where it is predicted to cause a loss of FGFR3
function.12 Therefore, both p.R621H and p.V700E cause a
dominantly inherited loss of FGFR3 function and similar
skeletal anomalies.
For several reasons, it is unlikely that the loss of function
caused by p.R621H results from haploinsufﬁciency. First,
mice heterozygous for an Fgfr3 null allele are phenotyp-
ically normal.4,5 Second, deletion of FGFR3, which occurs
in most patients with Wolf-Hirschhorn syndrome (WHS
[MIM 194190]), is not associated with any of the skeletal
defects observed in the individuals with p.R621H.13 How-
ever, it is possible that other genes that are typically de-
leted in patients withWHSmask the effect of FGFR3hemi-
zygosity. Third, the ﬁbroblasts of individuals affectedwith
CATSHL syndrome express both wild-type and mutant
(i.e., p.R621H-containing) FGFR3 RNA in nearly equal pro-
portions, and the expression levels of all ﬁve FGFRs in
patients are similar to those of normal individuals. Fur-
thermore, both mutant and wild-type FGFR3 localizes to
its normal position in the cell membrane (data not
shown). These observations suggest that p.R621H might,
instead, cause loss of FGFR3 function by a dominant neg-
ative mechanism.
Proper FGF signaling requires dimerization of FGFRmol-
ecules on the cell surface. Dimerization subsequently pro-
motes the intracellular autophosphorylation of critical ty-
rosine residues in the activation loop of the receptor.6 This
stabilizes the tyrosine kinase domain in the active con-
formation, leading to phosphorylation of other tyrosine
residues in the activation domain and binding of target
proteins. p.R621H-FGFR3 might form a heterodimer with
wild-type FGFR3 that reduces or abolishes kinase activity.
This mechanism has been shown to underlie the domi-
nant negative effect of several amino acid substitutions in
the activation domain of the insulin receptor (MIM
147670), another tyrosine kinase receptor, that cause
dominantly inherited insulin resistance.14,15
It has been speculated that polymorphisms in FGFR3
might inﬂuence adult height.16 This hypothesis is sup-
ported by the observation that several FGFR3 mutations
cause such mild forms of HCH that the height of affected
individuals falls within the normal spectrum.16 On the
other hand, p.V700E is positively correlated with long-
bone length in sheep, and the height of p.R621H heter-
ozygotes overlaps with individuals on the taller end of the
normal height spectrum. Analogous to the positive asso-
ciation between the level of FGFR3 activation and bone-
growth inhibition (i.e., higher levels of FGFR3 activation
cause more-severe limb shortening), our results indicate
that increases in long-bone length are associated with
FGFR3 impairment. This observation suggests that human
stature might be inﬂuenced by FGFR3 activity in a dose-
dependent fashion.
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